TR200201071T2 - Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi - Google Patents

Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi

Info

Publication number
TR200201071T2
TR200201071T2 TR2002/01071T TR200201071T TR200201071T2 TR 200201071 T2 TR200201071 T2 TR 200201071T2 TR 2002/01071 T TR2002/01071 T TR 2002/01071T TR 200201071 T TR200201071 T TR 200201071T TR 200201071 T2 TR200201071 T2 TR 200201071T2
Authority
TR
Turkey
Prior art keywords
agonists
retinoid antagonists
rar selective
emphysema
selective retinoid
Prior art date
Application number
TR2002/01071T
Other languages
English (en)
Turkish (tr)
Inventor
Nanette Belloni Paola
Klaus Michael
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200201071T2 publication Critical patent/TR200201071T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR2002/01071T 1999-10-19 2000-10-13 Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi TR200201071T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (1)

Publication Number Publication Date
TR200201071T2 true TR200201071T2 (tr) 2002-08-21

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01071T TR200201071T2 (tr) 1999-10-19 2000-10-13 Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi

Country Status (33)

Country Link
US (1) US6300350B1 (OSRAM)
EP (1) EP1225878B1 (OSRAM)
JP (2) JP4074458B2 (OSRAM)
KR (1) KR100485581B1 (OSRAM)
CN (1) CN1201730C (OSRAM)
AR (1) AR029648A1 (OSRAM)
AT (1) ATE344661T1 (OSRAM)
AU (1) AU777325B2 (OSRAM)
BR (1) BR0015225A (OSRAM)
CA (1) CA2387844C (OSRAM)
CY (1) CY1105941T1 (OSRAM)
CZ (1) CZ20021657A3 (OSRAM)
DE (1) DE60031790T2 (OSRAM)
DK (1) DK1225878T3 (OSRAM)
ES (1) ES2274810T3 (OSRAM)
HR (1) HRP20020329A2 (OSRAM)
HU (1) HUP0203295A3 (OSRAM)
IL (1) IL149151A0 (OSRAM)
JO (1) JO2178B1 (OSRAM)
MA (1) MA26835A1 (OSRAM)
MX (1) MXPA02003843A (OSRAM)
MY (1) MY129001A (OSRAM)
NO (1) NO328738B1 (OSRAM)
NZ (1) NZ518118A (OSRAM)
PE (1) PE20010678A1 (OSRAM)
PL (1) PL357499A1 (OSRAM)
PT (1) PT1225878E (OSRAM)
RS (1) RS50165B (OSRAM)
RU (1) RU2257383C2 (OSRAM)
TR (1) TR200201071T2 (OSRAM)
TW (1) TWI288639B (OSRAM)
WO (1) WO2001030326A1 (OSRAM)
ZA (1) ZA200202576B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2003024921A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
MXPA04002305A (es) 2001-09-18 2004-06-29 Hoffmann La Roche Agonistas ii de retinoides de urea sustituida.
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
JP4926707B2 (ja) 2003-08-22 2012-05-09 ダニスコ エイ／エス 封入化抗菌材料
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
EP2089017A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
US9963439B2 (en) 2013-08-20 2018-05-08 University Of Washington Through Its Center For Commercialization Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
WO2015041809A2 (en) 2013-08-26 2015-03-26 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
BR9407317A (pt) * 1993-08-19 1996-04-16 Janssen Pharmaceutica Nv Derivados vasoconstritores da diidrobenzopirana
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
ATE185799T1 (de) * 1995-02-24 1999-11-15 Hoffmann La Roche Retinoide
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
EP1030662B1 (en) * 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
DE60014928T2 (de) * 1999-08-02 2006-03-09 F. Hoffmann-La Roche Ag Retinoide zur behandlung von emphysem
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
KR20020043640A (ko) 2002-06-10
AR029648A1 (es) 2003-07-10
EP1225878B1 (en) 2006-11-08
HK1051002A1 (zh) 2003-07-18
IL149151A0 (en) 2002-11-10
CY1105941T1 (el) 2011-04-06
JP2007302689A (ja) 2007-11-22
HUP0203295A2 (hu) 2003-01-28
DK1225878T3 (da) 2007-03-05
EP1225878A1 (en) 2002-07-31
BR0015225A (pt) 2002-07-16
WO2001030326A1 (en) 2001-05-03
HRP20020329A2 (en) 2004-04-30
CZ20021657A3 (cs) 2002-10-16
DE60031790D1 (de) 2006-12-21
NO328738B1 (no) 2010-05-03
ATE344661T1 (de) 2006-11-15
TWI288639B (en) 2007-10-21
PT1225878E (pt) 2007-01-31
CA2387844A1 (en) 2001-05-03
DE60031790T2 (de) 2007-09-20
US6300350B1 (en) 2001-10-09
JO2178B1 (en) 2003-04-23
AU777325B2 (en) 2004-10-14
ZA200202576B (en) 2003-09-23
CA2387844C (en) 2009-04-14
YU29002A (sh) 2005-06-10
JP4850791B2 (ja) 2012-01-11
RU2257383C2 (ru) 2005-07-27
KR100485581B1 (ko) 2005-04-27
NZ518118A (en) 2004-02-27
MXPA02003843A (es) 2002-09-30
RS50165B (sr) 2009-05-06
PE20010678A1 (es) 2001-07-04
NO20021823L (no) 2002-04-18
MY129001A (en) 2007-03-30
NO20021823D0 (no) 2002-04-18
AU1137401A (en) 2001-05-08
CN1382042A (zh) 2002-11-27
JP2003512418A (ja) 2003-04-02
PL357499A1 (pl) 2004-07-26
CN1201730C (zh) 2005-05-18
MA26835A1 (fr) 2004-12-20
HUP0203295A3 (en) 2003-04-28
JP4074458B2 (ja) 2008-04-09
ES2274810T3 (es) 2007-06-01

Similar Documents

Publication Publication Date Title
TR200201071T2 (tr) Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR032293A1 (es) Estuche farmaceutico
ATE336229T1 (de) Zusammensetzung auf der basis polymerer mizellen
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
DE69739165D1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
TR200100054T2 (tr) Paroksetin metansülfonat
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
DE60044674D1 (de) Verwendung von rhamnolipiden zur wundheilung, behaund periodontaler regeneration
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ES2166577T3 (es) Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos.
TR200103271T2 (tr) İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
BRPI0611526A2 (pt) composição tópica contendo gelatina
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados